Cutaneous paraneoplastic syndromes. Dermatological manifestations associated with malignancies
DOI:
https://doi.org/10.12775/JEHS.2025.78.57535Keywords
cutaneous paraneoplastic syndromes, paraneoplastic conditions, skin manifestations, neoplasmAbstract
Introduction and purpose: Paraneoplastic syndromes (PS) are conditions associated with malignant tumours whose mechanism of onset is not fully understood. It is postulated that it’s pathophysiology may involve metabolic, endocrine, haematological changes and autoimmune reactions. The aim of this study is to describe cutaneous PS that nearly always occur with neoplasms. The work aims to give an overview of their clinical manifestations and to indicate the neoplasms they are most commonly associated with.
Description of the state of knowledge: Several types of cutaneous PS are almost always associated with malignancies. These include conditions like acroceratosis paraneoplastica, paraneoplastic pemphigus, erythema gyratum repens, acquired hypertrichosis lanuginosa, necrolytic migratory erythema, tripe palms, and syndromes such as AESOP syndrome, ectopic ACTH syndrome, and carcinoid syndrome. These dermatoses present a wide range of clinical features, including skin lesions that vary in appearance, severity, and location, and they are linked to different types of tumors. The connection between cutaneous PS and underlying neoplasms involves various potential pathophysiological mechanisms. However, the exact processes driving these relationships remain unclear and are the subject of ongoing research.
Conclusions: Awareness of cutaneous PS is crucial for early malignancy detection. Timely identification of these skin manifestations allows for quicker diagnosis and treatment of underlying neoplasm, significantly improving the patient's prognosis.
References
[1] da Silva JA, Machado Igreja AC de S, Freitas AF, Carvalho Costa IM, Mesquita K de C, Naves Lucas ICR, et al. Paraneoplastic cutaneous manifestations: concepts and updates. An Bras Dermatol 2013;88:9–22. https://doi.org/10.1590/S0365-05962013000100001.
[2] Rudnicka L, Olszewska M, Rakowska A, Sar-Pomian M. Wspolczesna dermatologia. vol. 2. I. PZWL; 2022.
[3] Stone SP, Buescher LS. Life-threatening paraneoplastic cutaneous syndromes. Clin Dermatol 2005;23:301–6. https://doi.org/10.1016/J.CLINDERMATOL.2004.06.011.
[4] Fonia A, Baran R. Cutaneous Paraneoplastic Syndromes with Nail Involvement. Dermatol Clin 2021;39:175–82. https://doi.org/10.1016/j.det.2020.12.003.
[5] Elise Kleyn C, Lai-Cheong JE, Bell HK. Cutaneous Manifestations of Internal Malignancy Diagnosis And Management. Am J Clin Dermatol 2006;7:71–84. https://doi.org/DOI:10.2165/00128071-200607020-00001.
[6] Bolognia JL, Schaffer J V., Cerroni L. Dermatology. 4th ed. Elsevier; 2018.
[7] Svoboda SA, Huang S, Liu X, Hsu S, Motaparthi K. Paraneoplastic pemphigus: Revised diagnostic criteria based on literature analysis. J Cutan Pathol 2021;48:1133–8. https://doi.org/10.1111/cup.14004.
[8] Yong AA, Tey HL. Paraneoplastic pemphigus. Australasian Journal of Dermatology 2013;54:241–50. https://doi.org/10.1111/j.1440-0960.2012.00921.x.
[9] Vassileva S, Drenovska K, Manuelyan K. Autoimmune blistering dermatoses as systemic diseases. Clin Dermatol 2014;32:364–75. https://doi.org/10.1016/j.clindermatol.2013.11.003.
[10] Anhalt GJ, Kim S, Stanley JR, Korman NJ, Jabs DA, Kory M, et al. Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med 1990;323:1729–35. https://doi.org/10.1056/NEJM199012203232503.
[11] Camisa C, Helm TN. Paraneoplastic pemphigus is a distinct neoplasia-induced autoimmune disease. Arch Dermatol 1993;129:883–6.
[12] Zimmermann J, Bahmer F, Rose C, Zillikens D, Schmidt E. Clinical and immunopathological spectrum of paraneoplastic pemphigus. J Dtsch Dermatol Ges 2010;8:598–605. https://doi.org/10.1111/J.1610-0387.2010.07380.X.
[13] Kartan S, Shi VY, Clark AK, Chan LS. Paraneoplastic Pemphigus and Autoimmune Blistering Diseases Associated with Neoplasm: Characteristics, Diagnosis, Associated Neoplasms, Proposed Pathogenesis, Treatment. Am J Clin Dermatol 2017;18:105–26. https://doi.org/10.1007/S40257-016-0235-Z.
[14] Paolino G, Didona D, Magliulo G, Iannella G, Didona B, Mercuri SR, et al. Paraneoplastic Pemphigus: Insight into the Autoimmune Pathogenesis, Clinical Features and Therapy. Int J Mol Sci 2017;18. https://doi.org/10.3390/IJMS18122532.
[15] Eckstein J, Healy E, Jain A, Hawkins D, Ho QA, Agrawal A, et al. A series of typical and atypical cases of Bazex syndrome: Identifying the red herring to avoid delaying cancer treatment. Clin Case Rep 2020;8:2259. https://doi.org/10.1002/CCR3.3133.
[16] Räßler F, Goetze S, Elsner P. Acrokeratosis paraneoplastica (Bazex syndrome) – a systematic review on risk factors, diagnosis, prognosis and management. Journal of the European Academy of Dermatology and Venereology 2017;31:1119–36. https://doi.org/10.1111/jdv.14199.
[17] Shah MH, Ferrazzano C, Karthikeyan A, Hejazi H, Bhattacharya A, Andrew Awuah W, et al. Bazex Syndrome (Acrokeratosis Paraneoplastica): A Narrative Review of Pathogenesis, Clinical Manifestations, and Therapeutic Approaches. Cureus 2023. https://doi.org/10.7759/cureus.45368.
[18] Kaszuba A, Szepietowski J, Adamski Z. Dermatologia geriatryczna. vol. III. I. Czelej; 2016; 449-461
[19] Cohen PR, Grossman ME, Almeida L, Kurzrock R. Tripe Palms and Malignancy. J Clin Oncol 1989;7:669–78. https://doi.org/DOI:10.1200/JCO.1989.7.5.669.
[20] Gammel JA. Erythema gyratum repens; skin manifestations in patient with carcinoma of breast. AMA Arch Derm Syphilol 1952;66:494–505. https://doi.org/10.1001/ARCHDERM.1952.01530290070010.
[21] Eubanks LE, McBurney E, Reed R. Erythema gyratum repens. Am J Med Sci 2001;321:302–5. https://doi.org/10.1097/00000441-200105000-00002.
[22] Rongioletti F, Fausti V, Parodi A. Erythema gyratum repens is not an obligate paraneoplastic disease: a systematic review of the literature and personal experience. J Eur Acad Dermatol Venereol 2014;28:112–5. https://doi.org/10.1111/J.1468-3083.2012.04663.X.
[23] Boyd AS, Neldner KH, Menter A. Erythema gyratum repens: A paraneoplastic eruption. J Am Acad Dermatol 1992;26:757–62. https://doi.org/10.1016/0190-9622(92)70107-Q.
[24] Votquenne N, Richert B. Erythema Gyratum Repens. JAMA Dermatol 2020;156:912. https://doi.org/10.1001/jamadermatol.2020.1694.
[25] Bakos N, Krasznai G, BÉGÁny Á. Erythema Gyratum Repens an Immunological Paraneoplastic Dermatosis. Pathol Oncol Res 1997;3:59–61. https://doi.org/10.1007/BF02893355.
[26] van Beek AP, de Haas ERM, van Vloten WA, Lips CJM, Roijers JFM, Canninga-van Dijk MR. The glucagonoma syndrome and necrolytic migratory erythema: a clinical review. Eur J Endocrinol 2004;151:531–7. https://doi.org/10.1530/EJE.0.1510531.
[27] John AM, Schwartz RA. Glucagonoma syndrome: a review and update on treatment. J Eur Acad Dermatol Venereol 2016;30:2016–22. https://doi.org/10.1111/JDV.13752.
[28] Tolliver S, Graham J, Kaffenberger BH. A review of cutaneous manifestations within glucagonoma syndrome: necrolytic migratory erythema. Int J Dermatol 2018;57:642–5. https://doi.org/10.1111/IJD.13947.
[29] Mullans EA, Cohen PR. Iatrogenic necrolytic migratory erythema: a case report and review of nonglucagonoma-associated necrolytic migratory erythema. J Am Acad Dermatol 1998;38:866–73. https://doi.org/10.1016/S0190-9622(98)70478-5.
[30] Turner M. Case of a woman whose face and body in two or three weeks’ time became covered with a thick crop of short and white downy hair. Med Times Gazette 1865;2:507.
[31] Frank JA, Rojek N, Foreman RS. A case of hypertrichosis lanuginosa acquisita as a sign of malignancy. Eur J Dermatol 2017;27:66–7. https://doi.org/10.1684/EJD.2016.2901.
[32] Wyatt JP, Anderson HF, Greer KE, Cordoro KM. Acquired hypertrichosis lanuginosa as a presenting sign of metastatic prostate cancer with rapid resolution after treatment. J Am Acad Dermatol 2007;56. https://doi.org/10.1016/J.JAAD.2006.07.011.
[33] Vulink AJE, Huinink DTB. Acquired hypertrichosis lanuginosa: a rare cutaneous paraneoplastic syndrome. J Clin Oncol 2007;25:1625–6. https://doi.org/10.1200/JCO.2007.10.6963.
[34] Slee PHTJ, Van Der Waal RIF, Schagen Van Leeuwen JH, Tupker RA, Timmer R, Seldenrijk CA, et al. Paraneoplastic hypertrichosis lanuginosa acquisita: uncommon or overlooked? Br J Dermatol 2007;157:1087–92. https://doi.org/10.1111/J.1365-2133.2007.08253.X.
[35] Alexandraki KI, Grossman AB. The ectopic ACTH syndrome. Rev Endocr Metab Disord 2010;11:117–26. https://doi.org/10.1007/S11154-010-9139-Z.
[36] Moon HR, Won CH, Chang SE, Lee MW, Choi JH, Moon KC. Generalised hyperpigmentation caused by ectopic adrenocorticotropic hormone syndrome with recurrent thymic neuroendocrine carcinoma. Australas J Dermatol 2015;56:131–3. https://doi.org/10.1111/AJD.12195.
[37] Isidori AM, Lenzi A. Ectopic ACTH Syndrome. Arq Bras Endocrinol Metab 2007;51:1217–25. https://doi.org/DOI:10.1590/s0004-27302007000800007.
[38] Oleinikov K, Avniel-Polak S, Gross DJ, Grozinsky-Glasberg S. Carcinoid Syndrome: Updates and Review of Current Therapy. Curr Treat Options Oncol 2019;20. https://doi.org/10.1007/S11864-019-0671-0.
[39] Gade AK, Olariu E, Douthit NT. Carcinoid Syndrome: A Review. Cureus 2020;12. https://doi.org/10.7759/CUREUS.7186.
[40] Rubin de Celis Ferrari AC, Glasberg J, Riechelmann RP. Carcinoid syndrome: update on the pathophysiology and treatment. Clinics (Sao Paulo) 2018;73. https://doi.org/10.6061/CLINICS/2018/E490S.
[41] Ito T, Lee L, Jensenc RT. Carcinoid-syndrome: recent advances, current status and controversies. Curr Opin Endocrinol Diabetes Obes 2018;25:22–35. https://doi.org/10.1097/MED.0000000000000376.
[42] Lipsker D, Rondeau M, Massard G, Grosshans E. The AESOP (adenopathy and extensive skin patch overlying a plasmacytoma) syndrome: report of 4 cases of a new syndrome revealing POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes) syndrome at a curable stage. Medicine 2003;82:51–9. https://doi.org/10.1097/00005792-200301000-00005.
[43] Lenormand C, Marzolf G, Lipsker D. AESOP syndrome: a potential life-saving and early clue to the diagnosis of POEMS syndrome. Clin Dermatol 2021;39:215–9. https://doi.org/10.1016/J.CLINDERMATOL.2020.10.002.
[44] Rongioletti F, Failla MC, Atzori L, Ferreli C. Skin manifestations of POEMS and AESOP syndrome in the same patient revealing plasma cell dyscrasia. J Cutan Pathol 2016;43:1167–71. https://doi.org/10.1111/CUP.12798.
[45] Dagrosa AT, Cowdrey MCE, LeBlanc RE, Lansigan F, Kaur P, Carter JB. Adenopathy and extensive skin patch overlying a plasmacytoma with unusual histologic findings in a patient with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes syndrome and Castleman disease. J Cutan Pathol 2019;46:784–9. https://doi.org/10.1111/CUP.13514.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Paulina Polańska, Marta Gruszka, Martyna Zakrocka, Maria Kubicka
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 56
Number of citations: 0
